BioCardia (BCDA)
(Delayed Data from NSDQ)
$2.49 USD
-0.21 (-7.78%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.49 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.49 USD
-0.21 (-7.78%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.49 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Zacks News
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include TAL Education Group (TAL), BioCardia (BCDA), Angi (ANGI), Xcel Energy (XEL) and SoFi Technologies (SOFI).
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
by Zacks Equity Research
The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
by Zacks Equity Research
BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
by Zacks Equity Research
Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -13.33% and 87.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -5.88% and 21.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will High Costs & Low Sales Dent Braskem (BAK) Q1 Earnings?
by Zacks Equity Research
Braskem's (BAK) upward cost trajectory is likely to have continued in the first quarter due to higher feedstock prices in international markets and global supply chain constraints.
Ovintiv (OVV) Q1 Earnings Coming Up: Here's How It Will Fare
by Zacks Equity Research
Ovintiv's (OVV) first-quarter earnings are expected to have benefited from the surge in oil and natural gas prices.
Will Suncor (SU) Reverse the Previous Miss in Q1 Earnings?
by Zacks Equity Research
Suncor Energy (SU) is expected to have benefited from the surge in oil realizations.
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
by Zacks Equity Research
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -109.09% and 11.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 42.86% and 49.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will BioCardia, Inc. (BCDA) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.